Cargando…
Predictors of the Therapeutic Response to Intralesional Bivalent HPV Vaccine in Wart Immunotherapy
Variable intralesional immunotherapies have recently been proposed as a means of achieving a successful eradication of recurrent and recalcitrant human papillomavirus (HPV)-induced cutaneous and anogenital warts. The bivalent HPV vaccine is one of the newly proposed immunotherapeutic agents. We inve...
Autores principales: | Hammad, Noha M., Marei, Ayman, El-Didamony, Gamal, Mortada, Zeinb, Elradi, Mona, Afifi, Amira Hamed Mohamed, Kadry, Heba M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621280/ https://www.ncbi.nlm.nih.gov/pubmed/34835211 http://dx.doi.org/10.3390/vaccines9111280 |
Ejemplares similares
-
Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine
por: Garg, Shilpa, et al.
Publicado: (2014) -
Intralesional bivalent and quadrivalent human papillomavirus vaccines didn’t significantly enhance the response of multiple anogenital warts when co-administered with intralesional Candida antigen immunotherapy. A randomized controlled trial
por: Fawzy, Manal, et al.
Publicado: (2023) -
The management of vulvovaginal warts using intralesional Bacillus Calmette–Guérin immunotherapy
por: Gupta, Sunil Kumar
Publicado: (2020) -
Immunotherapy with Intralesional Candida Albicans Antigen in Resistant or Recurrent Warts: A Study
por: Majid, Imran, et al.
Publicado: (2013) -
Triple Intralesional Antigen Immunotherapy versus Monoantigen in the Treatment of Multiple Recalcitrant Warts
por: Nofal, Ahmad A., et al.
Publicado: (2022)